Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas-Reference-Cited by-同舟云学术

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Published:2023-01 Issue:1 Volume:41 Page:210-225.e5
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Sworder Brian J.^ORCID,Kurtz David M.,Alig Stefan K.,Frank Matthew J.,Shukla Navika,Garofalo Andrea,Macaulay Charles W.,Shahrokh Esfahani Mohammad,Olsen Mari N.,Hamilton James,Hosoya Hitomi,Hamilton Mark,Spiegel Jay Y.,Baird John H.,Sugio Takeshi,Carleton Mia,Craig Alexander F.M.,Younes Sheren F.,Sahaf Bita,Sheybani Natasha D.,Schroers-Martin Joseph G.,Liu Chih Long,Oak Jean S.,Jin Michael C.,Beygi Sara,Hüttmann Andreas,Hanoun Christine,Dührsen Ulrich,Westin Jason R.,Khodadoust Michael S.,Natkunam Yasodha,Majzner Robbie G.,Mackall Crystal L.,Diehn Maximilian,Miklos David B.,Alizadeh Ash A.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference67 articles.

1. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N. Engl. J. Med.,2017

2. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N. Engl. J. Med.,2018

3. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma;Wang;N. Engl. J. Med.,2020

4. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N. Engl. J. Med.,2021

5. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N. Engl. J. Med.,2019

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. Validation of a PD-1/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma;iScience;2024-09

3. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future;Blood Reviews;2024-09

4. Prospects for liquid biopsy approaches in lymphomas;Leukemia & Lymphoma;2024-08-10

5. Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma;HemaSphere;2024-08